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Bacterial infections are associated with cardiovascular 
disease in Iran: a meta-analysis
Farzad Khademi1, Hamid Vaez2, Amir Abbas Momtazi-Borojeni3, Araz Majnooni4, Maciej Banach5,6, 
Amirhossein Sahebkar7,8,9
A b s t r a c t
Introduction: The present study aimed to assess the prevalence and associa-
tion of various bacterial infections with cardiovascular disease (CVD) in Iran.
Material and methods: An electronic search was performed using related 
keywords in the national and international databases up to June 30, 2017. 
Out of the 1807 articles found on the associations between bacterial infec-
tions and CVD, 20 relevant studies were selected for the meta-analysis.
Results: The prevalence of bacterial infections was higher in case groups 
compared with the control groups. Odds ratios for assessing the association 
between Chlamydia pneumonia infection and CVD based on PCR, IgG and IgA 
tests were 7.420 (95% CI: 3.088–17.827), 3.710 (95% CI: 1.361–10.115) and 
2.492 (95% CI: 1.305–4.756), respectively. Moreover, the calculated odds ratio 
for Mycoplasma pneumonia infection was 1.815 (95% CI: 0.973–3.386). For 
Helicobacter pylori infection, odds ratios based on IgG and IgA tests were 
3.160 (95% CI: 1.957–5.102) and 0.643 (95% CI: 0.414–0.999), respectively.
Conclusions: The present meta-analysis suggested that there was a signif-
icant association between H. pylori, C. pneumonia and M. pneumonia infec-
tions and CVD in Iran. These findings confirm the potential role of bacterial 
infections as predisposing factors for CVD.
Key words: bacterial infection, cardiovascular disease, meta-analysis, Iran.
Introduction
Cardiovascular disease (CVD) is a major cause of death all over the 
world [1, 2]. Atherosclerosis is a chronic inflammatory disease in the vas-
Cardiovascular Disease
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cular walls [3, 4] that is initiated and progresses 
via an interplay among multiple factors including 
proinflammatory cytokines and acute phase pro-
teins such as C-reactive protein (CRP) and fibrin-
ogen [5]. Coronary artery atherosclerosis is a key 
risk factor in the development of acute coronary 
syndrome [6].
Among various established clinical and labora-
tory risk factors associated with the pathogene-
sis of CVD (e.g. diabetes, hypertension, hyperlip-
idemia, dyslipidemia and smoking), several lines 
of evidence have shown that bacterial pathogens 
may play a main role [1, 4, 7, 8]. Bacterial infec-
tions can contribute to CVD mainly through in-
teraction with inflammatory and immunological 
pathways, either directly or indirectly [1]. Infec-
tion has been found to directly impair endothelial 
function by circulating endotoxins, induce prolif-
eration of smooth muscle cells and local inflam-
mation, and activate the innate immune response 
[9]. On the other hand, indirect damaging effects 
of bacterial infections include induction of proin-
flammatory, hypercoagulability and atherogenic 
responses, oxidation of low-density lipoprotein, 
antigen mimicry between bacterial and host cells, 
induction of nutrient/vitamin malabsorption, and 
metabolic disruptions such as excess production 
of ammonia. To sum up, repeated exposure to 
bacterial infections leads to an excess inflamma-
tory process leading to the provocation of immune 
responses that adversely affect cardiovascular risk 
factors such as triglycerides, high-density lipopro-
tein, C-reactive protein, heat shock proteins, cyto-
kines, fibrinogen, and white blood cell count. Dif-
ferent bacterial species related to the risk of CVD 
include Helicobacter pylori, Chlamydia pneumonia, 
Mycoplasma pneumonia and Porphyromonas gin-
givalis [7–11].
In Iran, a developing country in the Middle East, 
atherosclerosis is a prevalent disease with a high 
morbidity and mortality burden [7]. The associa-
tion between CVD and bacterial infections is not 
fully known in the Iranian population and some 
studies have emphasized the existence of a rela-
tionship, while others have not found any associa-
tion. Therefore, we aimed to investigate the possi-
ble relationship between main bacterial infections 
and CVD among Iranian patients using a system-
atic review and meta-analysis approach.
Material and methods
Search strategy 
Up to June 30, 2017, a comprehensive search of 
publications was performed on the relationship be-
tween bacterial infections and CVD in Iran using both 
Persian- and English-language databases includ-
ing Scientific Information Database (www.sid.ir), 
Irandoc (www.irandoc.ac.ir), Iranmedex (www.iran-
medex.ir) and Magiran (www.magiran.com) as well 
as PubMed, MEDLINE, Scopus, Google Scholar and 
ISI web of knowledge. The following search terms 
were selected from the MeSH database: “heart dis-
eases” OR “cardiovascular diseases” OR “coronary 
artery disease” OR “atherosclerosis” OR “myocar-
dial infarction” OR “ischemic heart disease” AND 
“bacterial infections” OR “H. pylori” OR “C. pneu-
monia” OR “P. gingivalis” OR “M. pneumonia” 
OR “bacterial periodontal diseases” AND “Iran”. 
Additional related articles were obtained through 
scanning the reference lists and hand searching. 
Drafting the systematic reviews and meta-analysis 
was based on the PRISMA checklist [12].
Study eligibility criteria
After evaluating article titles, abstracts and key-
words, case-control studies were selected based 
on the eligibility criteria including: 1) case-control 
studies published in Persian and English languag-
es, 2) assessing the relationship between bacterial 
infections and CVD in Iran, and 3) reporting the 
prevalence of CVD only in humans. Exclusion crite-
ria were: 1) studies published in other languages, 
2) articles except cross-sectional or case-control 
studies, 3) cross-sectional studies without a con-
trol comparator, 4) papers without full text, 5) Per-
sian articles without an English abstract, 6) review 
articles, 7) duplicate studies, for which only the 
most recent reports were included, 8) studies pre-
sented in conferences as abstracts, 9) assessment 
of relationships between viral, fungal and parasit-
ic infections with CVD, and 10) evaluated the prev-
alence rate of bacterial infection and CVD alone.
Data collection process
To reduce possible bias and mistakes, data ex-
traction from each included study was performed 
by independent authors. Two reviewers extracted 
data after reviewing the title, abstract and full 
text of papers and the following information was 
then extracted and summarized in Table I [13–31]: 
1) first author’s surname, 2) year of the study, 
3) area (city) of the study, 4) mean age for case 
and control groups, 5) gender (F/M) ratio for case 
and control groups, 6) number of patients with 
different types of CVD, 7) CVD type, 8) type and 
number of bacterial infections, and 9) bacterial in-
fection detection techniques. 
Data synthesis
Comprehensive Meta-Analysis (CMA) software 
version 2.2 (Biostat, Englewood, NJ, USA) was 
used for statistical analysis and the association 
between bacterial infections and CVD was ex-
pressed as odds ratio (OR) and 95% confidence in-
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terval (95% CI). Risk of publication bias was eval-
uated using Begg’s and Egger’s tests. Existence 
of heterogeneity across studies was determined 
using the Cochrane Q test and the inconsistency 
index (I2). In the case of small and large hetero-
geneity, fixed- and random-effects models were 
used to pool the results. In all analyses, p < 0.05 
was considered as statistically significant.
Results
Study characteristics
As shown in the flow diagram, a total of 20 case- 
control studies were obtained on the relationship 
between different bacterial infections and CVD in 
Iran up to June 30, 2017. Briefly, 1807 original ar-
ticles were collected from various national and in-
ternational databases. After title, abstract and full 
text screening, 1792 articles were omitted based 
on exclusion criteria. Five articles were includ-
ed after assessing the references and the meta- 
analysis was performed on 20 selected articles. 
Several papers were excluded because they had 
no effect on meta-analysis results. These select-
ed papers were from Tehran (5 studies), Isfahan 
(3 studies), Rafsanjan (2 studies), and Mashhad, 
Tabriz, Shiraz, Ahwaz, Qazvin, Qom, Bandar Abbas, 
Bushehr, Birjand, and Jahrom (each with 1 study) 
(Figure 1). Profiles of selected studies in the meta- 
analysis are listed in Table I [13–30]. Serological 
tests were the most important techniques used 
for the diagnosis of bacterial infections in patients 
with CVD in Iran. The most common type of CVD 
was atherosclerotic CVD. 
The association between C. pneumonia 
infection and CVD
In Iran, a total of 8 relevant studies evaluated 
the association between C. pneumonia infection 
and CVD (Table I). Molecular and serological meth-
ods were the most important diagnostic tests for 
the detection of C. pneumonia infection. Based 
on PCR, IgG and IgA tests, C. pneumonia infection 
prevalence in case groups was 22.7% (46/202), 
56.6% (200/353), and 53.6% (110/205), respec-
tively. However, in control groups, the positive rate 
of C. pneumonia infection on the basis of PCR, IgG 
and IgA tests was 2.9% (5/172), 25.7% (73/283), 
and 29.2% (48/164), respectively. Odds ratios for 
the association between C. pneumonia infection 
and CVD based on PCR, IgG and IgA tests were 
7.420 (95% CI: 3.088–17.827), 3.710 (95% CI: 
1.361–10.115) and 2.492 (95% CI: 1.305–4.756), 
respectively (Figure 2). 
There was low heterogeneity of the included 
studies; therefore, we used a fixed-effect model for 
assessing the association between C. pneumonia 
infection and CVD on the basis of PCR (p = 0.829, 
I2 = 0%) and IgA (p = 0.480, I2 = 0%). However, 
based on the IgG test (p = 0.002, I2 = 75.7%), 
a random-effects model was used to demonstrate 
the association between infection and disease. As 
shown in Table II, Begg’s and Egger’s tests were 
used to evaluate publication bias of studies.
The association between M. pneumonia 
infection and CVD
There were only 2 studies evaluating the as-
sociation between M. pneumonia infections and 
CVD in Iran. IgG-based serologic testing was the 
only method used to detect M. pneumonia infec-
tion (Table I). In the present study, the prevalence 
rate of M. pneumonia infection on the basis of the 
IgG test in case and control groups was 66.6% 
(90/135) and 54.8% (74/135), respectively. More-
over, the calculated odds ratio for M. pneumonia 
infection was 1.815 (95% CI: 0.973–3.386).
A  fixed-effect model was applied, due to low 
heterogeneity (p = 0.252, I2 = 23.7%), to pool re-
sults and to evaluate the association between 
M. pneumonia infection and CVD on the basis of 
IgG (Figure 3). 
The association between H. pylori infection 
and CVD
As shown in Table I, using serologic tests, the 
association between H. pylori infection and CVD 
was assessed in 10 articles in Iran. Based on IgG, 
the prevalence of H. pylori infection among case 
and control groups was 70.9% (918/1294) and 
39.2% (476/1213), respectively. Furthermore, the 
calculated odds ratio was 3.160 (95% CI: 1.957–
5.102) (Figure 4 A). Based on IgA, the prevalence 
of H. pylori infection was 48.4% (79/163) for case 
groups and 58.9% (99/168) for control groups. The 
calculated odds ratio for H. pylori infection was 
0.643 (95% CI: 0.414–0.999) (Figure 4 B).
Finally, to pool the results of the IgG-based 
H. pylori test (p < 0.001, I2 = 83%), a random-ef-
fects model was used, and for the IgA-based H. 
pylori test (p = 0.427, I2 = 0%), a fixed-effect model 
was used.
Discussion
The risk factors for the emergence and develop-
ment of CVD are not the same in different patients 
[15]. More than a century ago, potential roles of in-
fectious organisms including bacteria and viruses 
as potent risk factors in the induction of heart dis-
eases were investigated in several epidemiological 
studies [31]. Chlamydia pneumonia, a Gram-nega-
tive and obligate intracellular bacterium, was the 
first proposed etiologic agent responsible for the 
induction of inflammation in the vessel walls of 
patients with CVD [31, 32]. In Iran, the prevalence 
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International and national databases (PubMed, Medline, 
Scopus, Google Scholar, and ISI web of knowledge, SID, 
Irandoc, IranMedex, and Magiran) N = 1807 
260 studies selected for abstract evaluation
72 studies selected for full text evaluation 
Selected papers (n = 20)
5 studies included by checking the 
references 
1547 studies excluded due to: 
unrelated title, duplicate publications, 
unrelated topic 
188 studies excluded due to: congress 
abstract, articles presented in 
languages except English or Persian, 
systemanc review, no case-control 
study
57 studies excluded due to: non-
relevant articles, insufficient data, 
duplicate studies, animal studies
Figure 1. Flow diagram of select studies
A
Study   Statistics for each study Z-value P-value          Exposed/Total            Odds ratio and 95% CI
name Odds ratio Lower limit Upper limit   Cases Controls 
Dabiri 14.891 0.802 276.530 1.812 0.070 6/33 0/31  
Sadeghian 3.102 0.121 79.228 0.685 0.494 1/30 0/30  
Assar 6.667 2.412 18.430 3.657 < 0.001 25/85 5/85  
Bahrmand 17.543 1.001 307.398 1.961 0.050 14/54 0/24  
 7.420 3.088 17.827 4.481 < 0.001 
B
Study   Statistics for each study Z-value P-value          Exposed/Total            Odds ratio and 95% CI
name Odds ratio Lower limit Upper limit   Cases Controls 
Ashtari 1.585 0.653 3.848 1.018 0.309 11/42 15/82  
Bahrmand 124.871 7.145 2182.421 3.307 0.001 39/54 0/24  
Karimi 10.657 3.768 30.200 4.458 < 0.001 48/58 9/29  
Iranpour 1.556 0.530 4.568 0.804 0.421 9/90 6/90  
Zibaeenezhad 2.028 0.919 4.475 1.750 0.080 93/109 43/58 
 3.710 1.361 10.115 2.562 0.010  
C
Study   Statistics for each study Z-value P-value          Exposed/Total            Odds ratio and 95% CI
name Odds ratio Lower limit Upper limit   Cases Controls 
Ashtari 3.080 0.914 10.383 1.814 0.070 7/42 5/82  
Bahrmand 11.362 0.649 205.875 1.666 0.096 10/54 0/24  
Zibaeenezhad 2.028 0.919 4.475 1.750 0.080 93/109 43/58  
 2.492 1.305 4.756 2.768 0.006 
Figure 2. Forest plot of C. pneumonia infection associated with heart disease risk in Iran. A – PCR, B – IgG, C – IgA-
based tests
 0.01 0.1 1 10 100
 0.01 0.1 1 10 100
 0.01 0.1 1 10 100
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of C. pneumonia infection in patients with CVD 
is rather high [14]. However, there are confus-
ing results about the role of C. pneumonia in the 
pathogenesis of the disease in Iran and the world. 
For example, Sadeghian et al. [20], Zibaeenezhad 
et al. [27], West et al. [33] and Apfalter et al. [34] 
did not find a  link between C. pneumonia infec-
tion and CVD, while Dabiri et al. [14], and Sessa 
et al. [35] found a  significant correlation. These 
differences in results may be due to the variations 
in sampling, population size, applied detection 
technique, ethnicity, region, and disease type [21]. 
In the present study, the prevalence of C. pneu-
monia infection was higher in case groups com-
pared with control groups, as detected by PCR, 
IgG and IgA tests (Figures 2 A–C). In addition, 
our findings showed that the detection rate of 
C. pneumonia using molecular methods was lower 
than the serological methods in both case (22.7% 
vs. 56.6% and 53.6%) and control groups (2.9% 
vs. 25.7% and 29.2%). Based on the molecular 
detection methods, the prevalence of C. pneumo-
nia among Iranian subjects with CVD (22.7%) was 
higher than in India (10%) [36] and Turkey (15%) 
[37], and lower than in Poland (27%) [38] and Ja-
pan (62%) [39]. Our results support the notion 
that there is a  significant association between 
C. pneumonia and CVD risk in the Iranian people.
Helicobater pylori, a  Gram-negative and mi-
croaerophilic bacterium, colonizes the stomach 
of approximately 50% of the world’s population 
and is involved in gastritis, peptic ulcer, adeno-
carcinoma and MALT lymphoma [40–42]. There is 
inconsistent evidence on the association between 
H. pylori infection and CVD risk in Iran. Khodaii 
et al. [13] reported a significant association between 
H. pylori infection and CVD. In contrast, no asso-
ciation was found between H. pylori infection and 
CVD in a study reported by Eskandarian et al. [43]. 
In the present meta-analysis, we found a signifi-
cant correlation between H. pylori infection and 
CVD risk in Iran based on the IgG test (OR = 3.160, 
p < 0.001). However, there was no relationship be-
tween H. pylori infection and CVD based on the 
IgA test (OR = 0.643, p = 0.049). One reason for 
this inconsistency could be the low number of 
studies in the latter category (n = 2). Two studies 
from Poland and Germany showed a  significant 
association between H. pylori infection (detected 
according to genotypic and serological methods, 
respectively) and CVD risk [38, 44]. In contrast, 
one study from Austria did not suggest a main role 
for H. pylori infection in CVD [45]. The existence of 
these conflicting results suggests that the use of 
highly sensitive and specific methods is necessary 
to confirm the hypothetical relationship between 
infectious agents and the development of CVD.
In recent studies, it was suggested that the 
smallest pathogenic cause of atypical pneumonia 
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in human is M. pneumonia, which is a  common 
respiratory tract microorganism related to CVD 
risk either alone or along with other risk factors 
[46]. However, in Iran, only 2 studies assessed 
this possible risk using serological tests (Table I). 
In the present study, the obtained odds ratio for 
M. pneumonia infection among case groups with 
CVD was 1.815. It suggests that M. pneumonia in-
fection may be a risk factor for CVD. Similar find-
ing were reported in Saudi Arabia [46], Japan [47], 
the Netherlands [48] and Germany [44]. Inconsis-
tently with our results, the role of M. pneumonia 
infection in the etiopathogenesis of CVD has been 
refuted in some studies [38, 45]. Various sensitiv-
ity and specificity values for different diagnostic 
tests for detecting M. pneumonia infection in pa-
tients with CVD may be an important reason for 
discrepancies in the results obtained in different 
studies [48]. In this meta-analysis, no study was 
found on the association between P. gingivalis in-
fection and resulting bacterial periodontal infec-
tions and CVD risk in Iran. Finally, we recommend 
evaluation of the association between cardiovas-
cular risk factors and biomarkers such as plasma 
low- and high-density lipoprotein (LDL and HDL) 
and vitamin D status with various bacterial infec-
tions that predispose to CVD [49–51].
In conclusion, the present systematic review 
focused on the association between different bac-
terial infections and CVD risk in Iran. Our meta- 
analysis revealed that H. pylori, C. pneumonia and 
M. pneumonia infections could be considered as 
potential risk factors for CVD in Iran. These find-
ings are worthwhile to confirm the role of bac-
terial infections as predisposing factors for CVD 
and also explore the bacterial species that have 
a  stronger association with CVD. Based on the 
present findings, efficient and timely eradication 
of H. pylori, C. pneumonia and M. pneumonia in-
fections could be a useful strategy to reduce the 
burden of CVD. This study was limited in several 
ways including heterogeneity of diagnostic tests 
used for the detection of infections, and lack of 
a complete spectrum of studied bacterial species 
in relation to CVD. Furthermore, our analysis was 
limited to Iran, and a global investigation will be 
crucial for generalization of the findings. Based 
on the mentioned limitations, additional studies 
A
Study   Statistics for each study Z-value P-value          Exposed/Total            Odds ratio and 95% CI
name Odds ratio Lower limit Upper limit   Cases Controls 
Khodaii 7.765 5.829 10.344 14.007 < 0.001 330/500 100/500 
Nozari 2.154 0.977 4.747 1.903 0.057 56/70 39/60 
Davoudi 1.034 0.543 1.971 0.103 0.918 40/69 48/84 
Rogha 1.582 0.715 3.500 1.132 0.258 30/62 16/43 
Sarraf-Zadegan 13.219 5.096 34.292 5.308 < 0.001 36/52 8/55 
Vafaeimanesh 2.683 1.246 5.780 2.521 0.012 46/62 30/58 
Azarkar 2.872 1.478 5.582 3.112 0.002 42/73 25/78 
Jafarzadeh 5.879 2.719 12.713 4.502 < 0.001 107/120 35/60 
Nejad 2.579 0.944 7.049 1.847 0.065 84/90 76/90 
Alavi 3.464 1.787 6.715 3.679 < 0.001 79/96 55/96 
Ansari 2.173 1.204 3.924 2.575 0.010 68/100 44/89 
 3.160 1.957 5.102 4.708 < 0.001 
B
Study   Statistics for each study Z-value P-value          Exposed/Total            Odds ratio and 95% CI
name Odds ratio Lower limit Upper limit   Cases Controls 
Azarkar 0.777 0.409 1.477 –0.770 0.441 31/73 38/78 
Nejad 0.543 0.296 0.996 –1.974 0.048 48/90 61/90 
 0.643 0.414 0.999 –1.964 0.049 
Figure 4. Forest plot of H. pylori infections associated with heart disease risk in Iran. A – IgG, B – IgA-based tests
 0.01 0.1 1 10 100
 0.01 0.1 1 10 100
Study   Statistics for each study Z-value P-value          Exposed/Total            Odds ratio and 95% CI
name Odds ratio Lower limit Upper limit   Cases Controls 
Pourahmad 2.705 1.103 6.634 2.173 0.030 21/45 11/45  
Nejad 1.408 0.724 2.737 1.009 0.313 69/90 63/90  
 1.815 0.973 3.386 1.874 0.061 
Figure 3. Forest plot of M. pneumonia infection associated with heart disease risk in Iran (IgG-based test)
 0.01 0.1 1 10 100
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are needed to explain the difference between ob-
tained results on the basis of various bacterial in-
fection detection methods. Finally, the association 
between other bacterial infections and CVD risk in 
Iran merits further investigations.
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